Cargando…
Resveratrol in prostate diseases – a short review
INTRODUCTION: Resveratrol is a plant–derived polyphenol suggested to have many beneficial health effects, including antioxidant, anti–inflammatory, anti–proliferative, proapoptotic, and anti–angiogenic. It is even specu- lated that uptake of resveratrol by red wine consumption could be behind the so...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Urological Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936154/ https://www.ncbi.nlm.nih.gov/pubmed/24579014 http://dx.doi.org/10.5173/ceju.2013.02.art8 |
_version_ | 1782305279366397952 |
---|---|
author | Jasiński, Milosz Jasińska, Lidia Ogrodowczyk, Marcin |
author_facet | Jasiński, Milosz Jasińska, Lidia Ogrodowczyk, Marcin |
author_sort | Jasiński, Milosz |
collection | PubMed |
description | INTRODUCTION: Resveratrol is a plant–derived polyphenol suggested to have many beneficial health effects, including antioxidant, anti–inflammatory, anti–proliferative, proapoptotic, and anti–angiogenic. It is even specu- lated that uptake of resveratrol by red wine consumption could be behind the so–called French paradox the lower incidence of cardiovascular diseases in the French population. These properties, together with good absorption and tolerance, would make it an attractive agent in prostatic diseases, especially in cancer prevention and treatment. MATERIAL AND METHODS: MEDLINE search (keywords “prostate res- veratrol”) resulted in 39 research papers published since 2007. It has been shown that resveratol down–regulate androgen receptor expression, inhibit proliferation, and promote apop- tosis in prostate cancer cell lines and enhance their sensitivity to ionizing radiation. Several studies on animal prostate cancer development also suggest that resveratrol is able do delay or prevent carcino- genesis in prostate. Despite these promising results, there is no proof of any therapeutic properties of resveratrol in prostate diseases from human clinical trials nor any information about ongoing trials in this field. CONCLUSIONS: Resveratrol is produced and sold as a nutritional supplement, there is not enough clinical evidence to justify a recommendation for the administration of resveratrol in humans at present. |
format | Online Article Text |
id | pubmed-3936154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Polish Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-39361542014-02-26 Resveratrol in prostate diseases – a short review Jasiński, Milosz Jasińska, Lidia Ogrodowczyk, Marcin Cent European J Urol Review Paper INTRODUCTION: Resveratrol is a plant–derived polyphenol suggested to have many beneficial health effects, including antioxidant, anti–inflammatory, anti–proliferative, proapoptotic, and anti–angiogenic. It is even specu- lated that uptake of resveratrol by red wine consumption could be behind the so–called French paradox the lower incidence of cardiovascular diseases in the French population. These properties, together with good absorption and tolerance, would make it an attractive agent in prostatic diseases, especially in cancer prevention and treatment. MATERIAL AND METHODS: MEDLINE search (keywords “prostate res- veratrol”) resulted in 39 research papers published since 2007. It has been shown that resveratol down–regulate androgen receptor expression, inhibit proliferation, and promote apop- tosis in prostate cancer cell lines and enhance their sensitivity to ionizing radiation. Several studies on animal prostate cancer development also suggest that resveratrol is able do delay or prevent carcino- genesis in prostate. Despite these promising results, there is no proof of any therapeutic properties of resveratrol in prostate diseases from human clinical trials nor any information about ongoing trials in this field. CONCLUSIONS: Resveratrol is produced and sold as a nutritional supplement, there is not enough clinical evidence to justify a recommendation for the administration of resveratrol in humans at present. Polish Urological Association 2013-08-13 2013 /pmc/articles/PMC3936154/ /pubmed/24579014 http://dx.doi.org/10.5173/ceju.2013.02.art8 Text en Copyright by Polish Urological Association http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Paper Jasiński, Milosz Jasińska, Lidia Ogrodowczyk, Marcin Resveratrol in prostate diseases – a short review |
title | Resveratrol in prostate diseases – a short review |
title_full | Resveratrol in prostate diseases – a short review |
title_fullStr | Resveratrol in prostate diseases – a short review |
title_full_unstemmed | Resveratrol in prostate diseases – a short review |
title_short | Resveratrol in prostate diseases – a short review |
title_sort | resveratrol in prostate diseases – a short review |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936154/ https://www.ncbi.nlm.nih.gov/pubmed/24579014 http://dx.doi.org/10.5173/ceju.2013.02.art8 |
work_keys_str_mv | AT jasinskimilosz resveratrolinprostatediseasesashortreview AT jasinskalidia resveratrolinprostatediseasesashortreview AT ogrodowczykmarcin resveratrolinprostatediseasesashortreview |